#	Pagina
attuale pagina	/open-h2020/projects/217047/index.html
-1	/open-h2020/projects/205162/index.html
-2	/open-h2020/projects/218302/index.html
-3	/open-h2020/projects/196944/index.html

Opendata, web and dolomites

AuriGen SIGNED

Next Generation Left Atrial Appendage Implant to Treat Persistent Atrial Fibrillation

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

AuriGen project word cloud

Explore the words cloud of the AuriGen project. It provides you a very rough idea of what is the project "AuriGen" about.

mechanically electrical uk paf 30 laa isolation persistent caused irregular too specialist isolates treatment fitting complete distributors arrhythmia enter destroys pulses human muscle 13 occlusion doubled approval time first billion appendage procedure blood rates ce causing device clinical france entering atrial germany heart commercial financially approximately tissue international electrically wasted left surgical fit stream cardiac patients launch abnormal works permanently tier 5bn health redo heartbeat markets italy doubles risk incapable healthcare hours contraction 72 surgery expand stroke treating opening million amounting invasive services implant shut market prevent least minimally opportunity af therapy filter flow classified implants clots fibrillation shot

Project "AuriGen" data sheet

The following table provides information about the project.

Coordinator	AURIGEN MEDICAL LIMITED Organization address address: 18 CHURCHWELL SQUARE city: DUBLIN postcode: DUBLIN 13 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Ireland [IE]
Project website	http://www.aurigenmedical.com
Total cost	3˙503˙093 €
EC max contribution	2˙452˙165 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-2
Funding Scheme	SME-2
Starting year	2018
Duration (year-month-day)	from 2018-07-01 to 2020-06-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	AURIGEN MEDICAL LIMITED AURIGEN MEDICAL LIMITED Organization address address: 18 CHURCHWELL SQUARE city: DUBLIN postcode: DUBLIN 13 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IE (DUBLIN)	coordinator	2˙452˙165.00

Map

Project objective

Atrial Fibrillation (AF) is an irregular heartbeat that can lead to blood clots, high risk of stroke and heart failure. AF is caused by abnormal electrical activity in the heart. There are 10.7 million AF patients across Europe and the US, 3.6 million are classified as having Persistent AF (PAF). Surgical treatment for AF is a minimally invasive electrical therapy which destroys heart tissue causing the abnormal electrical pulses. For PAF patients, this works only 30% of the time. Approximately 72% of PAF patients require at least one redo procedure, amounting to €13.5 billion in wasted healthcare costs. Success rates are doubled if electrical activity in a part of the heart “the Left Atrial Appendage” (LAA), is shut down. But this increases stroke risk from blood clots as the LAA is now incapable of muscle contraction to maintain blood flow. LAA implants, “occlusion devices” fit across the opening of the LAA to filter the blood and prevent clots from entering the blood stream. However, fitting an occlusion device during the same procedure as LAA electrical isolation doubles procedure time (to 7 hours) making it non-financially viable for health services and too high risk for patients.

We have developed a unique, minimally invasive cardiac implant which permanently electrically and mechanically isolates the LAA in a one-shot procedure: treating both the stroke and arrhythmia risk associated with PAF with no increase in surgery time. EU and US PAF represents a $5bn/yr market opportunity. We will enter the market directly in our target Tier 1 European markets (Germany, France, Italy and UK). We will scale using specialist distributors to expand into further European, US and other international markets.

In this Phase 2 we will complete the technical, pre-clinical and first in human clinical studies required to achieve CE approval in Europe as well as market development work for commercial launch.

Deliverables

List of deliverables.
Sales Director Appointed	Other	2019-11-25 12:36:59
Operations Director Appointed	Other	2019-11-25 12:36:58

Take a look to the deliverables list in detail: detailed list of AuriGen deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AURIGEN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AURIGEN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Skye (2018)

Redefining Drone Safety and Autonomous Operation for Indoor Commercial Applications

VINOQUANT11SUPERPLUS (2019)

A digital based system for measuring, showing and regulation of the complexe system of wine feremtation with high precision via a Bluetooth -Refractometer, a Software and a Bluetooth Thermostat

Woodywood pickering (2019)

Bio-based (fully renewable) cost effective Polymer for new generation of ecological Coatings leveraging a disruptive innovation in the use of Pickering emulsion.